Discontinued — last reported Q3 '23
KLA Corporation Interest Paid decreased by 94.1% to $7.70M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 69.3%, from $25.06M to $7.70M. Over 4 years (FY 2021 to FY 2025), Interest Paid shows an upward trend with a 17.4% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in interest paid relative to debt levels may signal rising borrowing costs or higher leverage, while a decrease may indicate debt reduction or refinancing at lower rates.
The total cash outflow for interest payments on debt obligations, typically disclosed as a supplemental item in the cash...
Essential for comparing the cost of capital and debt burden across peers in the pharmaceutical industry.
cf_interest_paid| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $37.22M | $39.72M | $37.05M | $40.02M | $37.88M | $44.22M | $29.64M | $125.06M | $25.05M | $113.24M | $24.82M | $113.37M | $25.17M | $131.13M | $25.06M | $128.81M | $7.77M | $131.49M | $7.70M |
| QoQ Change | — | +6.7% | -6.7% | +8.0% | -5.3% | +16.7% | -33.0% | +322.0% | -80.0% | +352.1% | -78.1% | +356.8% | -77.8% | +420.9% | -80.9% | +414.0% | -94.0% | >999% | -94.1% |
| YoY Change | — | — | — | — | +1.8% | +11.3% | -20.0% | +212.5% | -33.9% | +156.1% | -16.3% | -9.3% | +0.5% | +15.8% | +1.0% | +13.6% | -69.1% | +0.3% | -69.3% |
We use cookies for analytics. See our Privacy and Cookie Policy.